The Korean journal of internal medicine

  • 제39권3호
  • /
  • Pages.501-512
  • /
  • 2024
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study

  • Ho-Young Yhim (Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital) ;
  • Yong Park (Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Jeong-A Kim (Department of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital) ;
  • Ho-Jin Shin (Department of Internal Medicine, Pusan National University Hospital) ;
  • Young Rok Do (Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Joon Ho Moon (Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University) ;
  • Min Kyoung Kim (Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine) ;
  • Won Sik Lee (Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Dae Sik Kim (Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Myung-Won Lee (Department of Internal Medicine, Chungnam National University College of Medicine) ;
  • Yoon Seok Choi (Department of Internal Medicine, Chungnam National University College of Medicine) ;
  • Seong Hyun Jeong (Department of Hematology-Oncology, Ajou University School of Medicine) ;
  • Kyoung Ha Kim (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Jinhang Kim (Department of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital) ;
  • Chang-Hoon Lee (Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital) ;
  • Ga-Young Song (Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Deok-Hwan Yang (Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Jae-Yong Kwak (Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital)
  • 투고 : 2023.06.19
  • 심사 : 2023.11.27
  • 발행 : 2024.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL). Methods: This multicenter prospective cohort study enrolled newly diagnosed patients with DLBCL (≥ 65 yr) between September 2015 and April 2018. A simplified geriatric assessment was performed at baseline using Activities of Daily Living (ADL), Instrumental ADL (IADL), and Charlson's Comorbidity Index (CCI). The primary endpoint was event-free survival (EFS). Results: The study included 249 patients, the median age was 74 years (range, 65-88), and 125 (50.2%) were female. In multivariable Cox analysis, ADL, IADL, CCI, and age were independent factors for EFS; an integrated geriatric score was derived and the patients stratified into three geriatric categories: fit (n = 162, 65.1%), intermediate-fit (n = 25, 10.0%), and frail (n = 62, 24.9%). The established geriatric model was significantly associated with EFS (fit vs. intermediate-fit, HR 2.61, p < 0.001; fit vs. frail, HR 4.61, p < 0.001) and outperformed each covariate alone or in combination. In 87 intermediate-fit or frail patients, the relative doxorubicin dose intensity (RDDI) ≥ 62.4% was significantly associated with worse EFS (HR, 2.15, 95% CI 1.30-3.53, p = 0.002). It was related with a higher incidence of grade ≥ 3 symptomatic non-hematologic toxicities (63.2% vs. 27.8%, p < 0.001) and earlier treatment discontinuation (34.5% vs. 8.0%, p < 0.001) in patients with RDDI ≥ 62.4% than in those with RDDI < 62.4%. Conclusions: This model integrating simplified geriatric assessment can risk-stratify older patients with DLBCL and identify those who are highly vulnerable to standard dose-intensity chemoimmunotherapy.

키워드

과제정보

This study was supported by Fund of Biomedical Research Institute, Jeonbuk National University Hospital, the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea Under Grand HR20C0021, and the Chonnam National University Hwasun Hospital Research Institute of Clinical Medicine under Grant HCRI22009.

참고문헌

  1. Lee H, Park HJ, Park EH, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat 2018;50:222-238. https://doi.org/10.4143/crt.2017.093
  2. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547-4553. https://doi.org/10.1002/cncr.24490
  3. Olivieri A, Gini G, Bocci C, et al. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist 2012;17:663-672. https://doi.org/10.1634/theoncologist.2011-0355
  4. Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 2012;17:838-846. https://doi.org/10.1634/theoncologist.2011-0417
  5. Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 2015;56:921-926. https://doi.org/10.3109/10428194.2014.953142
  6. Liu H, Zhang CL, Feng R, Li JT, Tian Y, Wang T. Validation and refinement of the age, comorbidities, and albumin index in elderly patients with diffuse large B-cell lymphoma: an effective tool for comprehensive geriatric assessment. Oncologist 2018;23:722-729. https://doi.org/10.1634/theoncologist.2017-0361
  7. Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol 2014;165:489-496. https://doi.org/10.1111/bjh.12765
  8. Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011;137:1079-1084. https://doi.org/10.1007/s00432-010-0973-x
  9. DuMontier C, Sedrak MS, Soo WK, et al. Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of Geriatric Oncology review paper. J Geriatr Oncol 2020;11:203-211. https://doi.org/10.1016/j.jgo.2019.08.005
  10. Bang HJ, Shim HJ, Kim GR, et al. Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients. Korean J Intern Med 2022;37:660-672. https://doi.org/10.3904/kjim.2021.324
  11. Choi JY, Kim KI. Assessing frailty using comprehensive geriatric assessment in older patients with hematologic malignancy. Blood Res 2022;57(S1):1-5. https://doi.org/10.5045/br.2022.2021134
  12. Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi. J Clin Oncol 2021;39:1214-1222. https://doi.org/10.1200/JCO.20.02465
  13. Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS. Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma. Br J Haematol 2016;173:487-491. https://doi.org/10.1111/bjh.13619
  14. Eyre TA, Martinez-Calle N, Hildyard C, et al. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. J Intern Med 2019;285:681-692. https://doi.org/10.1111/joim.12889
  15. Vidal L, Lando S, Vaxman I, et al. The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study. Leuk Lymphoma 2018;59:904-910. https://doi.org/10.1080/10428194.2017.1365856
  16. Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. Eur J Cancer 2018;99:86-96. https://doi.org/10.1016/j.ejca.2018.05.006
  17. Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv 2021;5:2426-2437. https://doi.org/10.1182/bloodadvances.2021004665
  18. Carson KR, Riedell P, Lynch R, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol 2015;6:211-218. https://doi.org/10.1016/j.jgo.2015.01.003
  19. Isaksen KT, Mastroianni MA, Rinde M, et al. A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL. Blood Adv 2021;5:4771-4782. https://doi.org/10.1182/bloodadvances.2021004777
  20. Vijenthira A, Mozessohn L, Nagamuthu C, et al. Frailty in patients with newly diagnosed diffuse large B-cell lymphoma receiving curative-intent therapy: a population-based study. J Natl Compr Canc Netw 2022;20:635-642.e9. https://doi.org/10.6004/jnccn.2022.7014
  21. Won CW, Yang KY, Rho YG, et al. The development of Korean Activities of Daily Living(K-ADL) and Korean Instrumental Activities of Daily Living(K-IADL) Scale. J Korean Geriatr Soc 2002;6:107-120.
  22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383. https://doi.org/10.1016/0021-9681(87)90171-8
  23. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068. https://doi.org/10.1200/JCO.2013.54.8800
  24. Yoo KH. Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDGPET/CT. Blood Res 2022;57(S1):75-78. https://doi.org/10.5045/br.2022.2022055
  25. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259. https://doi.org/10.1158/1078-0432.CCR-04-0713
  26. Harrell FE. Multivariable modeling strategies. In: Harrell FE, ed. Regression modeling strategies.Cham: Springer, 2015:63-102.
  27. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. https://doi.org/10.1056/NEJMoa011795
  28. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116. https://doi.org/10.1016/S1470-2045(08)70002-0
  29. Kim YR, Kim SJ, Park Y, et al. Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. Korean J Intern Med 2021;36:1181-1189. https://doi.org/10.3904/kjim.2020.206
  30. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468. https://doi.org/10.1016/S1470-2045(11)70069-9
  31. Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol 2017;4:e46-e55. https://doi.org/10.1016/S2352-3026(16)30171-5
  32. Olszewski AJ, Avigdor A, Babu S, et al. Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood 2022;140(Supplement 1):1778-1780.